article
Key Takeaways
Recent News
Read ArticleLance Rheumatology has published a large cohort analysis with a genome-first approach using whole exome sequencing to find 1 in 4026 prevalence (159/640092) of monogenic disorders, half with inflammatory features. Only one of these patients were previously diagnosed with an autoinflammatory disorder.
Dr. John Cush
Tweet
Tokyo study of 107 pts (age: ~86y) on synov. aspiration found to have CPPD crystals - MSU crystals also seen 17 pts (16%), where CPPD crystals predominated. 7/17 had Hx of gout or hyperuricemia. None were Rx for gout. https://t.co/lDnBhd5EFA https://t.co/9DjaLHygMc
Dr. John Cush
Tweet
Scleroderma Research Foundation Raises Nearly $1.1 Million At This Year's Cool Comedy • Hot Cuisine event hosted by Jeff Ross & included Fortune Feimster, Matt Friend, Ron Funches, Jay Pharoah, Lisa Ann Walter, Seth Green, Howie Mandel, and John Mayer https://t.co/ktgaNNinXa https://t.co/7RhaB9li9B
Dr. John Cush
Tweet
THIS SATURDAY IS National Prescription Drug Take Back Day - October 24, 2026, 10AM to 2PM (safe disposal of prescription drugs) FIND a center near you >> https://t.co/gle5p0G3fC https://t.co/OBjRaTPa9B
Dr. John Cush
Tweet
FDA has approved NDA for Evoxac, granting Cosette right to sell oral, liquid Evoxac as an alternative treatment option for managing dry mouth symptoms in Sjögren’s patients. NA until end of 2026. https://t.co/jTySNljXMv https://t.co/PCnfAmIB2W
Dr. John Cush
Tweet
🔎 Take a look at the long-term safety of a JAKi in patients with rheumatic disease in clinical trial and real-world settings
Explore the outcomes across >21,000 patient-years: https://t.co/QdAKpL3Vjv
Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/6Cw8p1msMT
Dr. John Cush
Tweet
Portugese single center study of primary Sjögren’s dz shows early damage is assoc w/ 12-14X incr risk of lymphoma. 208 pts (F/U 14_ yrs) Damage seen in 79% & 85%. Mortality linked to age but not damage. 17 (8%) had lymphoma. Early damage incr lymphoma (HR 14.5 or HR https://t.co/g62KtjDuWg
article
Systemic sclerosis (SSc) may have overlap features such as myositis. When present, myositis in SSc is associated with an increased risk of cardiac involvement and a shift in mortality away from ILD towards a greater cardiac risk.
article
An emerging technique called spatial frequency domain imaging (SFDI) proved its mettle for evaluating skin fibrosis in systemic sclerosis (SSc), also called scleroderma, in an early clinical study.
Dr. John Cush
Tweet
RheumNow Live 2027 registration is NOW OPEN.
GLP-1s in your clinic. CAR-T in lupus. Rheumatology experts vs. AI, with your vote.
Jan. 30–31 | Onsite + virtual
Early Bird Pricing through 12/15/2026.
See the agenda. Register: https://t.co/zYYC2350tE https://t.co/mPdcOhbrC6
Dr. John Cush
Tweet
Cryptococcus is rare, but twice as likely with JAK inhibitors. Retrospective TriNetX analysis of RA pts (>30k/grp) starting JAKi vs TNFi; JAKi vs non-TNFi; & TNFi vs non-TNF. Crypto seen in <0.2% in all groups; but signif higher HR for JAKi (HR 2.2 & 2.15) https://t.co/fJeKwDZABL
Dr. John Cush
Tweet
REVEAL study enrolled 418 early microscopic polyangiitis pts - High baseline (Pre-Rx) neutrophil-to-lymphocyte ratio (NLR > 10) was assoc w/ signif higer Dz activity (BVAS), alveolar hemorrhage, poor renal function, reduced survival & higher infection-related mortality (P = https://t.co/vXuRwXP9gc
Dr. John Cush
Tweet
Polish study compared comorbidities #s in incident RA & PsA. RA pts were older at dx (61 vs 44 yrs) & may drive higher rates in RA. 23/3 comorbidities (74%) were signif more prevalent in RA, including HTN (18 v 12%), ischemic HD (11 v 6%), cerebrovascular dz (4 vs 2%) https://t.co/l0RW6bVVHd
Dr. John Cush
Tweet
FDA has granted Fast Track designation to EG-501 (Evergreen), investigational Rx for cognitive impairment with neuropsychiatric systemic lupus erythematosus (NPSLE), following positive results from the phase 2 ClearMEMory study https://t.co/n9wO2wLLBk https://t.co/Vejldj5PlQ
Dr. John Cush
Tweet
No difference in MACE risk betw TNFi vs JAKi in 6174 RA pts. Korean claims data compared TNFi (n 5,152) vs JAKi (n 1,022) initiators. MACE risk was 4.1 & 3.6/1000PYs w/ TNFi vs JAKi, respectively. MACE risk did not differ significantly between JAKi and TNFi (adj HR 0.636; 0.283, https://t.co/035WSUQAhJ
Dr. John Cush
Tweet
Open Evidence study of 952 008 US clinicians (556K MDs), submitted 271 million AI clinical queries over 2.5 yrs study period. MDs submitted ~371 queries/mo - 33% for Rx & 14% fo Dx. Highest use w/ young MD, oncology, hematology, Int medicine, & family medicine https://t.co/FGErefxWD5
article
A new Frontiers in Immunology review from Ong, Wincup and colleagues, shows that lupus arthropathy is not a single uniform entity and it is biologically under-studied and clinically mismeasured, Moreover, the biology of lupus arthritis may shed light on choosing the best therapy for MSK manifestations of SLE.
Dr. John Cush
Tweet
Thai study of opportunistic infx in Pediatric SLE - 177 pSLE, & 38 developed OI (3.4/100PY). Most common OIs: Candida (27%), Aspergillus (13.5%), CMV (13.5%) - lung & skin mostly. Risk factors: Pulse steroids, Dz activity (SLEDAI-2K ≥11) https://t.co/0zjDOnDCEh https://t.co/H7JZ56ItDY
Dr. John Cush
Tweet
Should You Use Low Dose Naltrexone?
A recent review of 105 studies and 15 randomized controlled trials of LDN found that, across a range of disorders (chronic pain, autoimmune and neuroimmune disorders, gastrointestinal disease, dermatological conditions, post-infectious https://t.co/lmjJoGlFAZ
Video
From the Blog
The costs of GLP-1 agonists must come down in order to make these treatments available to the people who need them - including many people with rheumatologic diseases.
Podcasts
Troubles with ‘Gut Feelings’-
Don’t Hold the JAK (10.9.2026)
PsA Beyond the Joints: Rheum, Derm, and Gastro Perspectives-
Remission – Believe it or Not (10.2.2026)
Therapeutic Updates
Clinical dilemmas in axSpA and PsA
Sponsored by UCB
Explore some of the challenges rheumatologists face in clinical practice, including expert perspectives from UCB's Annual International Immunology Summit.
Read Post
PsA Beyond the Joints: Rheum, Derm, and Gastro Perspectives
Sponsored by AbbVie Medical Affairs + Health Impact
Dr. Saakshi Khattri hosts dermatologist Dr. Ahmad Amin and gastroenterologist Dr. Joshua Steinberg to discuss multidisciplinary care in PsA and other immune-mediated inflammatory diseases. Learn how signals in the skin and gut may prompt the need for collaboration across specialties to support better patient outcomes that extend beyond the joints.
Read Post
Obesity – Inflammation – PsA
Sponsored by Lilly Medical Affairs
Learn about the inflammatory intersection between Psoriatic Arthritis and Obesity, and why adiposity is more than a comorbidity.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
